Verve is a biotechnology company focused on discovering and developing therapies for coronary artery disease. It utilizes CRISPR (clustered regularly interspaced short palindromic repeats) and gene editing techniques to treat coronary artery and cardiovascular disease.
|Employees (est.) (Mar 2020)||29||(+16%)|
Verve Therapeutics total Funding
Verve Therapeutics latest funding size
Time since last funding
|a year ago|
Verve Therapeutics investors
|ARCH Venture Partners, GV, Biomatics Capital Partners, F-Prime Capital|
Verve Therapeutics has 910 Twitter Followers. The number of followers has increased 1.7% month over month and increased 15.9% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Verve Therapeutics founded?
Verve Therapeutics was founded in 2018.
Who are Verve Therapeutics key executives?
Verve Therapeutics's key executives are Kiran Musunuru, David Neafus and Keith Joung.
How many employees does Verve Therapeutics have?
Verve Therapeutics has 29 employees.
Who are Verve Therapeutics competitors?
Competitors of Verve Therapeutics include AID Genomics, Stealth BioTherapeutics and Genetron Health.
Where is Verve Therapeutics headquarters?
Verve Therapeutics headquarters is located at 215 First St #440, Cambridge.
Where are Verve Therapeutics offices?
Verve Therapeutics has an office in Cambridge.
How many offices does Verve Therapeutics have?
Verve Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies